Background and Aim: Major histocompatibility complex class I chain-related A (MICA) genetic variants and their serum levels (sMICA) were associated with the development of hepatitis C virus-related hepatocellular carcinoma (HCC) in untreated cohorts. The dynamic changes in serial sMICA levels and their association with HCC in the postcurative status are elusive. Methods: Single nucleotide polymorphism rs2596542 of MICA and serial sMICA levels were analyzed in chronic hepatitis C patients with a sustained virologic response after antivirals. Forty-two patients who developed HCC and 84 age-matched, gender-matched, and cirrhosis propensity score-matched non-HCC controls were compared. Serial sMICA levels were measured within 6 months before treatment initiation (pre-sMICA), 6 months after the end of treatment (post-sMICA), and on the last visit before the development (or not) of HCC (last-sMICA). Results: Cox regression analysis revealed that last-sMICA was the only predictive factor of HCC development (hazard ratio/95% confidence interval: 2.27 (per 1 log pg/mL increase)/ 1.672-3.082, P < 0.001). Patients without HCC development showed a significantly reduced trend of sMICA levels during follow-up (trend P = 0.001), which was observed only in GG genotype (trend P < 0.001) but not A allele carriers (P = 0.88). In contrast, patients with HCC showed an increased trend of sMICA levels (trend P = 0.024). However, only the GG genotype "high expressors" (trend P = 0.06) but not A allele carriers (P = 0.18) showed a correlation of substantially increased trend of sMICA levels and HCC development. Conclusions: Serial sMICA levels were associated with HCC development in SVR patients. The clinical utility of this finding is restricted to MICA rs2596542 GG genotype carriers.
Introduction
It is estimated that 71 million people have been infected with hepatitis C virus (HCV) worldwide. 1 Chronic hepatitis C (CHC) infection is a major disease burden, predisposing to liver complications such as hepatocellular carcinoma (HCC) . 2 Eradication of HCV by antiviral therapy greatly reduces the risk of HCC, albeit not entirely, because it still occurs in a substantial proportion of patients. [3] [4] [5] [6] [7] Several surrogate markers have been identified to try to predict HCC development in patients who have achieved a sustained virologic response (SVR). 4, 5, 8 In addition, host genetic factors may also predispose to the development of HCC.
A genome-wide association study demonstrated that the single nucleotide polymorphism (SNP) rs2596542 of the major histocompatibility complex class I chain-related A (MICA) gene and the serum protein levels (sMICA) were associated with HCVinduced HCC in untreated cohorts. 10 MICA is known as the ligand for the natural killer cell group 2D receptor (NKG2D), which activates natural killer cells and CD8 + T cells. Overproduction of soluble MICA in the circulation may downregulate NKG2D expression in immune cells and diminish NKG2D-mediated antitumor immunity. We recently identified that the SNP and MICA serum levels before antiviral therapy could predict HCC development in patients who failed to eradicate HCV. Cirrhotic non-SVR patients with high pretreatment sMICA levels or carrying the A allele were shown to beat great risk of developing HCC. However, the predictive values of the genetic variant and pretreatment sMICA levels in terms of HCC development are unclear in patients with an SVR. 3 It is unknown whether sMICA levels may fluctuate after viral eradication and whether dynamic changes in sMICA levels may correlate with the development of HCC in SVR patients. Here, we conducted a case-control study analyzing the association between serial sMICA levels and HCC development in patients with an SVR and carrying different MICA rs2596542genetic variants.
Methods
Eligible CHC patients were those with an SVR, defined as HCV-RNA seronegativity 24 weeks after completion of antiviral treatment with pegylated interferon alfa-2a or pegylated interferon alfa-2b plus ribavirin from 2007 to 2011. Patients were excluded if they were coinfected with human immunodeficiency virus or hepatitis B virus. Patients were also excluded if they had a history of excessive alcohol consumption (≥20 g daily) or showed any evidence of suffering from HCC prior to, during, or within 6 months of starting antiviral therapy. Patients were regularly monitored by means of posttreatment outpatient visits every 3-12 months. 4, 5 Patients who developed HCC during the posttreatment follow-up period and had completed serial sMICA available were enrolled in the study group. Another consecutive group consisting of agematched, gender-matched, and cirrhosis-matched patients without HCC were selected as controls with a 1:2 propensity score matching ratio. The follow-up duration for every control patient was equal to or longer than that of HCC patients to avoid selection bias. The diagnosis of HCC was confirmed by following international guidelines. 11, 12 Liver cirrhosis was diagnosed based on histopathologic examination of liver biopsies. 13 Before 2011, serum HCV-RNA was detected using qualitative real-time polymerase chain reaction (COBAS AMPLICOR Hepatitis C Virus Test, ver. 2.0; Roche, Branchburg, NJ, USA; detection limit: 50 IU/mL) and branched DNA quantification assays (Versant HCV-RNA 3.0; Bayer, Tarrytown, NY, USA; quantification limit: 615 IU/mL). Before 2011, HCV genotypes were determined using the Okamoto method.
14 After 2011, both the HCV-RNA and genotypes were detected using real-time polymerase chain reaction assays (Real Time HCV; Abbott Molecular, Des Plaines, IL, USA; detection limit: 12 IU/mL). 15 All patients provided a written informed consent, and the Institutional Review Board at Kaohsiung Medical University Hospital approved the protocols, which conformed with the guidelines of the International Conference on Harmonization for Good Clinical Practice.
MICA rs2596542 genotyping and measurement of sMICA levels. The SNP rs2596542 of the MICA gene was determined by ABI TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA) using predesigned, commercial genotyping assays (ABI Assay ID: C__27301153_10), as previously described. 3, 16 The allele and genotype frequencies were consistent with Hardy-Weinberg equilibrium. sMICA levels were measured by means of a sandwich enzyme-linked immunosorbent assay (DuoSet MICA ELISA kits; R&D Systems, Minneapolis, MN, USA). Serial sMICA levels were measured at three time points: within 6 months before treatment initiation (pre-sMICA), 6 months after the end of treatment (post-sMICA), and on the last visit before the development (or not) of HCC (last-sMICA).
Statistics. The frequency between groups was compared using the χ 2 test with the Yates correction or Fisher's exact test. Group means, presented as the mean values with standard deviations, were compared using analysis of variance and Student's t-test or the Mann-Whitney U-test. The serum HCV-RNA levels are expressed as the logarithmic transformation of the original values. Differences in sMICA levels between two time points were compared using the paired t-test or Wilcoxon signed rank test. The Cochran-Armitage test was used to evaluate the trends of serial changes in sMICA levels in patients with or without HCC. Furthermore, Cohen's d effect size power analysis was used for quantitative measurement of the magnitude of sMICA change on HCC occurrence between groups. The values of 0.2, 0.5, and 0.8 represent the strength of small, medium, and large effects. 17 Cox regression analysis was performed to evaluate independent factors associated with HCC by analyzing covariants with P values < 0.05 in the univariate analysis. The statistical analyses were performed using the SPSS 12.0 statistical package (SPSS, Chicago, IL, USA). All statistical analyses were based on two-tailed hypothesis tests with a significance level of P < 0.05.
Results
Patient characteristics. A total of 42 HCC patients and 84 age-matched, gender-matched, and cirrhosis-matched non-HCC controls were enrolled in the study. As shown in Table 1 , the mean age of the study population was 58.2 years, and 64.3% (n = 81) of the patients were male. Eighty-six patients (42.8%) had liver cirrhosis, and 68 patients (54.0%) carried the MICA rs2596542 A allele. The mean follow-up period after achieving an SVR was 46.4 months (range 6-119 months). The interval between the blood test to measure last-sMICA and HCC occurrence or not was 21.6 ± 15.6 months. The pre-sMICA, post-sMICA, and lastsMICA concentrations were 108.7 ± 142.3, 104.2 ± 248.3, and 131.9 ± 340.2 pg/mL, respectively. There was a significantly increased trend of sMICA from AA (19.8 + 21.3 pg/mL), AG (89.3 + 114.8 pg/mL), to GG (148.3 + 167.7 pg/mL) genotype carriage (trend P < 0.001).
Factors associated with HCC, including serial sMICA levels. Compared with patients without HCC, those with HCC had lower platelet counts, as well as higher levels of post-sMICA (197.4 ± 398.0 vs 57.6 ± 89.6 pg/mL, P = 0.03) and last-sMICA (320.4 ± 508.4 vs 37.7 ± 140.2 pg/mL, P < 0.001). Cox regression analysis revealed that last-sMICA was the only factor predictive of HCC development (hazard ratio [HR]/95% confidence interval [CI]: 2.27 (per 1 log pg/mL increase)/1.672-3.082, P < 0.001) ( Table 1) . Patients without HCC showed a significantly decreased trend of sMICA levels during follow-up (trend P = 0.001). In contrast, HCC patients showed an increased trend of sMICA levels (trend P = 0.024) (Fig. 1) . The difference in sMICA changes between the HCC and the non-HCC groups became more significant as time evolved (Table 2 and Fig. 2) .
Association of serial sMICA levels with HCC in patients with different MICA genetic variants. The expression levels of sMICA differ between patients with different MICA SNPs. 3, 16 We further analyzed the association of serial sMICA levels with HCC occurrence in patients with different MICA genetic variants.
Among MICA rs2596542 GG genotype carriers, patients with HCC showed significantly higher last-sMICA levels (445.5 ± 654.4 vs 9.8 ± 15.9 pg/mL, P < 0.001) ( Table 3) . A Cox regression analysis revealed that last-sMICA was the only factor predictive of HCC development (HR/CI: 2.22/1.450-3.401, P < 0.001) ( Table 4) . In MICA rs2596542 A allele carriers, patients with HCC showed significantly higher post-sMICA (164.7 ± 226.6 vs 56.0 ± 100.8 pg/mL, P = 0.01) and last-sMICA (206.7 ± 297.7 vs 60.7 ± 186.6 pg/mL, P = 0.003) levels (Table 3) . A Cox regression analysis revealed that last-sMICA was the only factor predictive of HCC (HR/CI: 2.54/1.544-4.164, P < 0.001) ( Table 4) .
GG genotype carriers without HCC showed a significantly decreased trend of sMICA levels during follow-up (trend P < 0.001). In contrast, HCC patients with the GG genotype showed a substantially increased trend of sMICA levels (trend P = 0.06) (Fig. 1) . However, these trends were not observed in A allele carriers, with or without HCC development (Table 1 ). In addition, significant differences in the changes of sMICA levels as time evolved between the HCC and non-HCC groups were seen only in patients with the GG genotype, not the A allele (comparison of △ sMICA at different time points between HCC and non-HCC patients; Table 2 and Fig. 2 ).
Discussion
Alternation of the levels of certain biomarkers before and after anti-HCV therapy may serve as predictors of HCC development. 8, 18 In this regard, the association of dynamic changes in serial sMICA levels occurring after anti-HCV treatment with the subsequent development of HCC is unclear. In the current study, we observed that sMICA levels varied in CHC patients with successful viral eradication. Elevated sMICA levels during the posttreatment period may serve as a surrogate marker for risk of HCC development in patients with an SVR. Compared with non-HCC patients, those who eventually developed HCC showed higher sMICA levels in the last visit, irrespective of their MICA genotypes. Moreover, there existed inverse presentations of serial sMICA levels between HCC and non-HCC patients. In contrast to HCC patients who had gradually increased sMICA levels, those without HCC had reciprocally decreased sMICA levels overtime. Intriguingly, these trends were seen only in patients who carried the MICA rs2596542 GG genotype but not the A allele. AST, aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard ratio; MICA, major histocompatibility complex class I chain-related A; r-GT, r-glutamyl transferase; sMICA, serum major histocompatibility complex class I chain-related A. Serum MICA in hepatocarcinoma C-F Huang et al.
High sMICA levels have been investigated as a marker for tumors with different etiologies, including HCC. 3, [19] [20] [21] [22] [23] In addition, the expression levels of sMICA differ between subjects who possess different MICA rs2596542 genotypes. Patients carrying the MICA rs2596542 A allele have lower levels of expression of sMICA than GG genotype carriers.
3,10 Kumar et al. reported that the percentage of high sMICA (defined as > 5 pg/mL) was 39%, 20%, and only 11% among hepatitis B virus-related HCC patients who carried GG, AG, and AA genotypes, respectively. 23 The current study comprising Taiwanese patients echoed the previous report that there existed a dose-dependent manner in terms of sMICA levels among patients who carried different numbers of G allele.
The risk allele identified in the genome-wide association study was by the comparison between CHC and HCC patients but not between CHC patients and uninfected controls, suggesting that AST, aspartate aminotransferase; ALT, alanine aminotransferase; DM, diabetes mellitus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MICA, major histocompatibility complex class I chain-related A; r-GT, r-glutamyl transferase; sMICA, serum major histocompatibility complex class I chain-related A.
the SNP is associated with progression from CHC to HCC rather than susceptibility to HCV infection. 10 It raised the issue that whether the SNP involved mainly in disease progression in terms of necroinflammation or/and fibrogenesis. Using cirrhotic patients without HCC as the controls may help to clarify the issue. We recently demonstrated that among cirrhotic patients who failed antivirals, there existed a 4.37-fold HCC risk for those A allele carriers compared with their counterparts after more than 4 years of follow-up. 3 As a consequence, the genetic locus may directly link to oncogenesis in Taiwanese CHC patients. We also identified that pretreatment sMICA levels could predict HCC development only in CHC patients in whom the antiviral therapy had failed. Thus, the predictive power of pretreatment sMICA levels for HCC would be eliminated in case of successful viral eradication. 3 Nevertheless, the impact of HCV eradication on sMCIA levels during the posttreatment period or even beyond was unclear. Whether these dynamic changes would be associated with HCC development also remained to be clarified. The results from this study indicate that among "high expressors" carrying the GG genotype in whom HCC did not develop, sMICA levels decreased gradually and significantly overtime, whereas sMICA levels remained consistently low in A allele carriers. In contrast, patients who developed HCC, in particular GG genotype carriers, showed a trend of increasing sMICA levels during the follow-up period. Only patients with the GG genotype, not A allele carriers, showed opposing sMICA levels over time depending on whether HCC developed or not. The pathophysiological mechanisms underlying these changes remain unknown. The MICA rs2596542 A allele has been recognized as a risk predictor of HCV-induced HCC. 3, 10 It has been postulated that low levels of membrane-bound MICA in A allele carriers may result in poor immune recognition and that reduced immune surveillance may increase the cancer risk. 10 In this regard, low serum levels would limit the clinical utility of sMICA as a predictive tool in A allele carriers. 3 On the other hand, it is more likely that MICA would be secreted into the serum by stressed cells in patients with the MICA rs2596542 GG genotype. 10 In CHC patients carrying the GG genotype, reduced inflammation as a result of successful HCV eradication would be accompanied by lower sMCIA production. In contrast, progressively increased sMICA levels would be a reflection of ongoing oncogenesis and were associated with cancer formation during the posttreatment follow-up period.
The current study was limited by failing to enroll a larger cohort. We attempted to minimize bias by checking the effect size and implementing the propensity score matching design, which adjusted most critical confounders for HCC, such as age, gender, and cirrhosis. In conclusion, serial sMICA levels may link to HCC development in CHC patients with curative antiviral therapy. Patients who eventually developed HCC had progressively elevated sMICA levels. In addition, the association of sMICA levels with HCC development showed genotypic differences. In patients carrying the MICA rs2596542 GG genotype, sMICA levels decreased overtime after viral eradication. In contrast, an increasing trend of sMICA levels indicates that attention should be paid at the possibility of HCC development. Currently, the study of the long-term outcome in the post-curative directly acting antivirals era is an unmet need. The finding would shed light for further validation in the directly acting antivirals cohort provided by longer follow-up period. CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; MICA, major histocompatibility complex class I chain-related A; sMICA, serum major histocompatibility complex class I chain-related A.
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